Agile Therapeutics Inc (NASDAQ:AGRX) – Investment analysts at Cantor Fitzgerald lowered their FY2017 earnings per share (EPS) estimates for shares of Agile Therapeutics in a research report issued on Monday, Zacks Investment Research reports. Cantor Fitzgerald analyst W. Tanner now anticipates that the specialty pharmaceutical company will earn ($0.97) per share for the year, down from their previous forecast of ($0.96). Cantor Fitzgerald has a “Buy” rating and a $5.00 price target on the stock. Cantor Fitzgerald also issued estimates for Agile Therapeutics’ FY2018 earnings at ($0.70) EPS.
Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03.
Shares of Agile Therapeutics (NASDAQ AGRX) opened at $3.28 on Thursday. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.14. Agile Therapeutics has a 12-month low of $1.93 and a 12-month high of $5.60. The stock has a market cap of $110.08, a price-to-earnings ratio of -3.57 and a beta of 2.01.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Pura Vida Investments LLC boosted its holdings in Agile Therapeutics by 65.9% during the third quarter. Pura Vida Investments LLC now owns 289,501 shares of the specialty pharmaceutical company’s stock worth $1,291,000 after purchasing an additional 115,000 shares during the last quarter. Neuberger Berman Group LLC acquired a new position in Agile Therapeutics during the third quarter worth $613,000. Alyeska Investment Group L.P. acquired a new position in Agile Therapeutics during the third quarter worth $3,747,000. Caxton Corp boosted its holdings in Agile Therapeutics by 12.1% during the third quarter. Caxton Corp now owns 1,820,012 shares of the specialty pharmaceutical company’s stock worth $8,117,000 after purchasing an additional 196,445 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new position in Agile Therapeutics during the third quarter worth $161,000. Institutional investors and hedge funds own 72.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “FY2017 Earnings Forecast for Agile Therapeutics Inc Issued By Cantor Fitzgerald (AGRX)” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://stocknewstimes.com/2018/01/14/cantor-fitzgerald-weighs-in-on-agile-therapeutics-incs-fy2017-earnings-agrx.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.